Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2A6 | P11509 | 3/20 | 0.50 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.50 |
| ▸ | ASIC3 | Q9UHC3 | 1/20 | 0.46 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.46 |
| ▸ | IDH1 | O75874 | 1/20 | 0.44 |
| ▸ | AGXT | P21549 | 1/20 | 0.43 |
| ▸ | ADRA1D | P25100 | 2/20 | 0.43 |
| ▸ | CTRC | Q99895 | 1/20 | 0.40 |
| ▸ | SLC5A2 | P31639 | 9/20 | 0.38 |
| ▸ | SLC5A1 | P13866 | 5/20 | 0.37 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.37 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.37 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28202032 | 0.85 | CYP2A6 (0.50) | CYP2A6ADRB2ASIC3LOXL2IDH1 | |
| SCHEMBL16018598 | 0.82 | CYP2A6 (0.50) | CYP2A6ADRB2ASIC3LOXL2IDH1 | |
| SCHEMBL16020862 | 0.80 | CYP2A6 (0.40) | CYP2A6ADRB2ASIC3LOXL2IDH1 | |
| SCHEMBL21697653 | 0.80 | CYP2A6 (0.40) | CYP2A6ADRB2ASIC3LOXL2IDH1 | |
| SCHEMBL28201450 | 0.79 | CYP2A6 (0.50) | CYP2A6ADRB2ASIC3LOXL2IDH1 | |
| SCHEMBL28954986 | 0.79 | CYP2A6 (0.50) | CYP2A6ADRB2ASIC3LOXL2IDH1 | |
| SCHEMBL16018691 | 0.79 | CYP2A6 (0.42) | CYP2A6ADRB2ASIC3LOXL2IDH1 | |
| SCHEMBL16018613 | 0.79 | CYP2A6 (0.47) | CYP2A6ADRB2ASIC3LOXL2IDH1 | |
| SCHEMBL16018639 | 0.79 | CYP2A6 (0.47) | CYP2A6ADRB2ASIC3LOXL2IDH1 | |
| SCHEMBL16018607 | 0.79 | CYP2A6 (0.47) | CYP2A6ADRB2ASIC3LOXL2IDH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9012412-B2 | Dual SGLT1/SGLT2 inhibitors | JANSSEN PHARMACEUTICA NV (BE) | 2015-04-21 | — | — | US | disclosed |
| US-20140256657-A1 | DUAL SGLT1/SGLT2 INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2014-09-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140256657-A1 | DUAL SGLT1/SGLT2 INHIBITORS | SLC5A1, SLC5A2, GLP1R | CYP2A6 646/4885ADRB2 528/4885ASIC3 632/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.